Every tirzepatide question, answered from the label and the trials

Compounded tirzepatide is made to order by a state-licensed 503A pharmacy and is not FDA approved. What it is, what it costs, and how to get it online.

No oral tirzepatide is FDA approved. Zepbound and Mounjaro are weekly injections, and compounded pills, drops and sublingual tablets have no trial data.

Tirzepatide reaches steady state after 4 weeks of weekly doses and starts at 2.5 mg for 4 weeks. Here is the timeline the label and trials support.

There is no published head-to-head trial of tirzepatide tablets against the injection. Here is what the injection trials show and how to read reviews.

Tirzepatide is a synthetic 39-amino-acid peptide that activates GIP and GLP-1 receptors. How the molecule works, and why research powder is not medicine.

Compounded tirzepatide is not FDA approved, so safety depends on the pharmacy, the prescriber and the vial label. Here is what to check and what FDA warns.

Some compounded tirzepatide includes B12 or glycine, and no trial has tested those mixes. Here is what the label says about B12 and what to ask a pharmacy.

No official tirzepatide diet exists. This plan follows the label: small meals, protein first, fluids and fiber to manage nausea, constipation and reflux.

Tirzepatide's half-life is about 5 days, so about 3% of a dose is left after 25 days. Here is the half-life chart and what it means if you stop.

The Zepbound savings card can bring the cost to $25 a month with commercial coverage. Without it, self-pay runs $299 to $699. Here are the options.

Tirzepatide can be taken at any time of day, with or without food. Pick one day a week and keep it. To switch days, leave at least 72 hours between doses.

The FDA declared the tirzepatide shortage resolved on December 19, 2024. Here is what that changed for compounders and what it means for you now.

Tirzepatide drops, herbal oral liquids and sublingual drops are not FDA approved and have no trial evidence. Zepbound and Mounjaro are injections only.

Zepbound costs $350-$450 in Mexico vs $1,060 in the U.S., but importation is federally illegal. Here's the actual math, legal risks, and alternatives.

No, tirzepatide should be clear and colorless. Red, pink, or cloudy medication signals contamination or degradation. What normal looks like and when to worry.

Some compounded tirzepatide vials add vitamin B6 (pyridoxine). No trial tested the mix, Zepbound and Mounjaro do not contain it, and the dose does not change.

Tirzepatide is not approved for inflammation. Its trials measured weight, blood sugar and sleep apnea. Here is what that evidence can and cannot say.

Tirzepatide is not approved to treat blood pressure. Neither label lists it as a use, and SURMOUNT-1 reports cardiometabolic gains alongside weight loss.

Mounjaro is Lilly's FDA-approved tirzepatide for type 2 diabetes. Compounded tirzepatide is pharmacy-made and not FDA approved. Here is the comparison.

Gray market tirzepatide means vials sold with no prescription, often labeled for research. What the FDA says, the risks, and how to verify a real pharmacy.

The closest medical alternative to tirzepatide is semaglutide. There is no over-the-counter version. See how the options compare on trial data and price.

Some compounded tirzepatide vials add L-carnitine. No trial tested the mix, the brands do not contain it, and your tirzepatide dose stays the same.

Your first week on tirzepatide is the 2.5 mg starting dose. Here is what the label says about it, the early side effects, and what month 1 looks like.

Compounded tirzepatide is not going away entirely. Mass copies tied to the FDA shortage ended; patient-specific 503A compounding continues.

Tirzepatide average weight loss per week works out to about 0.2% to 0.3% of body weight from the SURMOUNT-1 72-week means. Here is the arithmetic by dose.

Tirzepatide weight loss results: 15.0% to 20.9% average loss over 72 weeks in SURMOUNT-1, less with type 2 diabetes, more than semaglutide head to head.

Label maintenance doses are 5, 10 and 15 mg. SURMOUNT-4: continuing lost 5.5% more in a year; stopping regained 14.0%. What to do after goal weight.

Stopping tirzepatide: the drug clears in about 25 days, appetite returns, and SURMOUNT-4 showed 14.0% regain in a year. No withdrawal is on the label.

Tirzepatide tips from the label and trials: follow the 4-week dose steps, manage nausea and fluids, rotate sites, store cold, keep the diet plan.

The only trial-tested way to keep weight off after Zepbound is to keep taking it. If you stop, here is what the label and trials actually support.

Zepbound doses run 2.5 to 15 mg once weekly. See the titration schedule, the SURMOUNT-1 weight loss chart by dose, side effects by dose and vial prices.

Step-by-step protocol for microdosing compounded tirzepatide below 2.5 mg, including unit calculations, titration schedules, and side-effect mitigation.

Niacinamide (vitamin B3) is added to some compounded tirzepatide vials. It does not change the tirzepatide mg or unit math and has no trial data behind it.

Splitting tirzepatide into twice-weekly doses isn't FDA-approved, but some providers prescribe it for side effects. Here's what the evidence shows.

A tirzepatide dosing calculator needs your dose in mg, the vial concentration in mg/mL and a U-100 syringe. See the formula, worked examples and tables.

How to mix tirzepatide powder: add the bacteriostatic water volume on your pharmacy label, swirl without shaking, refrigerate, then draw units by mg/mL.

Yes, usually. The tirzepatide label allows a change of dosing day as long as 72 hours pass between doses. Here are the early, late and missed-dose rules.

Tirzepatide is labeled for once every 7 days. A 5-day interval is not a labeled schedule and raises weekly exposure by 40%. Here are the rules and math.

A red, itchy spot at a tirzepatide injection site is a listed common side effect that fades in days. What is normal, what is not, and how to reduce it.

Tirzepatide loses 8-14% potency per week above 86°F. Learn the exact temperature thresholds, how to tell if your medication is damaged, and when to replace it.

Mounjaro is a pen; syringes are for tirzepatide vials. Convert mg to units from the vial concentration, then inject in the belly, thigh or arm.

The definitive guide to needle gauge and length for tirzepatide injections, including pain reduction data, absorption differences, and when to switch.

Dizziness is not on the Zepbound label; dehydration and eating less explain most cases. Zepbound side effects in the first week, in females, and long term.

Yes. Fatigue is on the Zepbound label's list of common side effects. Why eating less, dehydration and poor sleep cause it, and when tiredness means call.

Anxiety is not a listed tirzepatide side effect. FDA removed the Zepbound mood warning in February 2026. What to do if your mood shifts.

Headache is not on the Zepbound or Mounjaro label's common side effect list. Why dehydration and eating less cause it, safe relief, and when to get care.

Yes. Acid reflux and indigestion are on the Mounjaro label. Why a slower stomach causes heartburn, what day 1 and week 1 feel like, and what helps.

Burping, indigestion and acid reflux are on the Zepbound label. Why a slower stomach causes gas and sulfur burps, the SURMOUNT-1 numbers, and eating tips.

Yes. In SURMOUNT-1, constipation affected 11.7% to 17.1% of adults on tirzepatide versus 5.8% on placebo. Fluids, fiber, movement, and when to call.

Tirzepatide slows stomach emptying, which is why nausea hit 24.6% to 33.3% of adults in SURMOUNT-1. How long it lasts, what relieves it, and warning signs.

Overdose symptoms, timeline, when to call 911, and what to do if you accidentally inject double your tirzepatide dose. Evidence-based emergency guide.

Palpitations are not on the tirzepatide label. A small rise in resting heart rate is a known class effect. Plausible causes and when to get care.

Feeling cold is not on the Zepbound or Mounjaro label. Eating much less, fat loss and dehydration are the plausible reasons. What helps and when to call.

Does tirzepatide cause cancer? The Zepbound and Mounjaro labels carry one cancer warning: thyroid C-cell tumors seen in rats, relevance to humans unknown.

No. The Zepbound label says to stop tirzepatide when pregnancy is recognized. The label facts on pregnancy, breastfeeding, and birth control pills.

Alcohol is not listed as a tirzepatide interaction on the Zepbound or Mounjaro label. The practical reasons for caution and when a drink is a bad idea.

Blood clots are not listed on the Zepbound or Mounjaro label. SURPASS-4 found no rise in major heart events. Here are the clot warning signs to know.

The Zepbound and Mounjaro labels do not list UTI or urine changes. Dehydration, ketones from fat loss and low fluid intake are the likely reasons.

SURMOUNT-5 head-to-head: tirzepatide cut body weight 20.2% vs 13.7% for semaglutide at 72 weeks. Mechanism, dosing, side effects and prices compared.

Tirzepatide is sold as Mounjaro (type 2 diabetes) and Zepbound (weight loss and sleep apnea). There is no generic, and compounded tirzepatide is not one.

Ozempic is semaglutide, a GLP-1 drug for type 2 diabetes. Tirzepatide hits GLP-1 and GIP and beat semaglutide 1 mg on A1c and weight in SURPASS-2.

No label or trial supports taking semaglutide and tirzepatide together or in the same week. Both act on the GLP-1 receptor. Switching is a prescriber decision.

Zepbound price drops expected 2029-2031 with biosimilar entry. Current cost-reduction strategies, insurance changes, and compounded alternatives.

Zepbound was approved for moderate to severe obstructive sleep apnea with obesity on December 20, 2024. In SURMOUNT-OSA, breathing events fell 25 to 29 an hour.

Mounjaro is not labeled for sleep apnea. Zepbound, the same drug (tirzepatide), was approved for moderate to severe OSA with obesity on December 20, 2024.